Wednesday 26 October

08:30–09:30Ageing with HIV: From Knowledge to Action
In collaboration with the European AIDS Treatment Group (EATG)

Chairs:Mario Cascio, European AIDS Treatment Group (EATG), Italy
Maryan Said, EATG, Oslo, Norway

08:30–08:34Welcome and introduction
Mario Cascio

08:34–08:55Community and clinical perspectives
Axel Vanderperre, UTOPIA_BXL, Brussels, Belgium
Rebecca Mbewe, Positively UK, London, UK
Giovanni Guaraldi, Infectious Diseases, University of Modena and Reggio Emilia,
Modena, Italy

08:55–09:15How to move forward: panel discussion and Q&A
Moderated by Brian West, EATG, Edinburgh, Scotland, joined by Axel Vanderperre,
Rebecca Mbewe, Giovanni Guaraldi, Maka Gogia,
EATG, Tblisi, Georgia,
and Esteban Martinez, Infectious Diseases, Hospital Clínic & University of
Barcelona, Spain

09:15–09:20Wrap up and summary remarks
Anton Basenko, Global Fund Advocates Network, Brussels, Belgium

09:20–09:30Call to action: improving the quality of life of older people living with HIV
Mario Cascio

09:30–10:30Poster Discussion Session
09:30–09:40Durable efficacy of switching from a three-/four-drug tenofovir alafenamide
(TAF)-based regimen to the two-drug regimen dolutegravir/lamivudine (DTG/3TC)
in the TANGO study through week 196
Jean-Paul Routy,
Infectious Diseases, McGill University Health Centre,
Montreal, Canada

09:40–09:50Impact of switch towards 3TC/dolutegravir on the intact and total viral reservoir
in the Rumba study
Linos Vandekerckhove,
Department of Internal Medicine and Pediatrics, HIV Cure
Research Center, Ghent University, Ghent, Belgium

09:50–10:00Prevalence, risk factors and the impact of antiretroviral treatment in SARS-CoV-2
infection in people with HIV: a cross-sectional study
Jose M Miro,
HIV Unit, Infectious Diseases Service, Hospital Clinic – August Pi i
Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona,
Barcelona, Spain

10:00–10:10Prevalence, outcomes, and factors associated with testing for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among people living
with HIV across Europe in the multinational EuroSIDA cohort
Olga Fursa,
Centre of Excellence for Health, Immunity and Infections,
Rigshospitalet, Copenhagen, Denmark

10:10–10:20The stability and predictors of change in clinically relevant multimorbidity
clusters over time among people with HIV in the Pharmacokinetic and clinical
Observations in PeoPle over fifty (POPPY) study
Luxsena Sukumaran,
Infection & Population Health, University College London,
London, UK

10:20–10:30Trends in maternal characteristics and pregnancy outcomes among
women living with HIV in the UK: 2014 to 2019
Helen Peters,
UCL Great Ormond Street Institute of Child Health, Integrated
Screening Outcomes Surveillance Service, London, UK

10:30–11:00Scientific Posters and Coffee

11:00–12:15Monkeypox: Where Are We Now and What Have We Learned?

Chairs:Alexandra Calmy, Geneva, Switzerland
Simon Collins, HIV i-base, London, UK


11:05–11:20Epidemiology of monkeypox and public health response

11:20–11:30Case definitions and evolution
Chloe Orkin,
London, UK

11:30–11:40Treatment, vaccines and guidelines
Sanjay Bhagani,
Infectious Diseases/HIV Medicine, Royal Free London Foundation
Trust, Research Department of Infection, UCL, London, UK; President, European
AIDS Clinical Society (EACS)

11:40–11:50The patient perspective
Harun Tulunay,
HIV, sexual health and mental health advocate;
Training and Volunteer Co-ordinator, Positively UK, London, UK

11:50–12:05Perceptions and understandings of media and public health messaging
about the monkeypox outbreak in the UK: findings from a rapid response,
co-produced survey
Including women in the public health response to the monkeypox (MPXV)
outbreak in the UK: findings from a rapid response, co-produced survey
Sara Paparini,
Wolfson Institute of Population Health and SHARE
Collaborative, Queen Mary University of London, London, UK

12:05–12:15Panel discussion, Q&A and close

12:15–13:30Late Breakers and Hot Topics

12:15–12:30Virological failure and HIV RNA re-suppression rates in four randomised trials
of dolutegravir, efavirenz or protease inhibitor-based treatment in
3116 participants
Andrew Hill,
Department of Pharmacology and Therapeutics, University of Liverpool,
Liverpool, UK

12:30–12:45Six-month outcomes of every 2-months long-acting cabotegravir and rilpivirine
in a real-world setting: effectiveness, adherence to injections and patient-
reported outcomes from PLWHIV in the German CARLOS cohort
Celia Jonsson-Oldenbüttel,
Clinical Care, Medizinisches Versorgungszentrum
München am Goetheplatz, Munich, Germany

12:45–13:00Expanded multivariable models to assist patient selection for long-acting
cabotegravir+rilpivirine treatment: clinical utility of a combination of patient,
drug concentration, and viral factors associated with virological failure over
152 weeks
Chloe Orkin,
Department of Immunobiology, Queen Mary University, London, UK

13:00–13:15Modeling and simulation to optimize islatravir once daily (QD) doses
in HIV treatment naïve and virologically suppressed populations
Ryan Vargo,
Merck & Co., Inc., Rahway, NJ, USA

13:15–13:30Total lymphocyte and CD4+ T-cell count changes in participants receiving
islatravir (0.25, 0.75 and 2.25 mg QD) and doravirine +/- lamivudine: post-hoc
analysis from a phase 2b dose-ranging study (P011)
Todd Correll,
Merck & Co., Inc., Rahway, NJ, USA

13:30–13:35Closing Remarks

13:35Lunch and Depart
Exhibition close. Lunch bags will be available for collection from the Forth Room
of the SEC.